Developer docs
API playgroundTry for free, no card

Search company profiles

Arctic Vision

Full company profile

uuid0002c5r

Namestring
Arctic Vision
Legal namestring
极目峰睿(上海)生物科技有限公司
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Arctic Vision is a Shanghai-based, privately held ophthalmic biopharmaceutical company founded in 2019 that develops and commercializes innovative therapies for retinal disease, dry eye, and ocular neuroprotection across China and the broader Asia-Pacific region. Its pipeline is anchored by ARVN001 (XIPERE® in the United States, ARCATUS®/锋脉® in Asia-Pacific), a proprietary triamcinolone acetonide suspension formulated for suprachoroidal administration via the patented SCS Microinjector® platform licensed from Clearside Biomedical; ARVN001 is the first and only approved suprachoroidal therapy globally for uveitic macular edema, with approvals from the US FDA, Australian TGA, and Singapore HSA, plus a New Drug Application formally accepted by China's CDE in January 2025. The company's portfolio additionally includes the iTEAR®/沁淯® extra-nasal neurostimulation device for drug-free dry eye treatment (launched in China in May 2024), gene therapy candidates ARVN601 and ARVN901, and multiple preclinical-to-Phase-II assets covering glaucoma, myopia, and presbyopia.

The company operates a dual-engine model that combines in-licensed pharmaceutical development with consumer-oriented device technologies, and in February 2026 announced an agreement to acquire MDCO Technology's ophthalmic device business (premium IOL, phakic lens, and refractive platforms), which will establish wholly-owned subsidiaries in Shanghai for biopharmaceutical R&D, Hangzhou for device manufacturing, and California for design and global collaboration. Commercially, Arctic Vision employs an enterprise field-sales model executed through strategic partnerships and direct regional operations: Santen Pharmaceutical holds exclusive China commercialization rights for ARVN001 (excluding Taiwan, Hong Kong, and Macau), with up to US$85 million in upfront and milestone payments due to Arctic Vision, while the company retains direct commercialization capabilities across Greater China, South Korea, ASEAN countries, India, Australia, and New Zealand.

Arctic Vision generates revenue primarily through licensing and milestone payments rather than direct product sales, with revenue mechanics dominated by upfront fees, development and regulatory milestones, and commercial milestones from partners such as Santen and Clearside Biomedical. The company is backed by Nan Fung Life Sciences, Pivotal bioVenture Partners, Morningside Ventures, Loyal Valley Capital, Tencent Investment, Octagon Capital, and Dr. Adrian Cheng, having raised approximately US$132 million across two disclosed rounds (US$32M Series A in 2020, US$100M Series B in 2021). Leadership is drawn from senior ophthalmic roles at Allergan China, Alcon, Novartis Basel, MSD, and Boehringer Ingelheim, with Founder, Chairman and CEO Dr. Eddy Wu holding 14 patents and 23 academic publications.

Short descriptiontext

Arctic Vision is a Shanghai-based private ophthalmic biopharmaceutical company developing breakthrough therapies for retinal disease, dry eye, and refractive conditions across Asia-Pacific, anchored by its SCS Microinjector platform and lead asset ARVN001 for uveitic macular edema.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersShanghai, China
HQ citystring
Shanghai
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices7 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
ophthalmic therapeutics, suprachoroidal drug delivery, retinal disease therapy, dry eye treatment, intraocular lens devices
Industry4 codes
PRIMARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals
SECONDARYHLAKAKAE
Retina & Vitreous Specialists
SECONDARYHLAHAJAH
Cataract Surgery Systems & IOLs (Phaco Systems, IOLs, Intraoperative Aberrometry, Viscoelastics)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHLAKAKAF
Cornea, External Disease & Refractive Surgery (LASIK/PRK)
NAICS code2 codes
  • Ophthalmic Goods Manufacturing339115
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code3 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Ophthalmic Goods3851
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Ophthalmic Pharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Licensing and milestone payments
TypeLicensing Royalties
Description

Arctic Vision generates revenue through licensing deals including upfront payments, development milestones, regulatory milestones, and commercial milestones. Example: Santen collaboration provides up to US$85 million in upfront and milestone payments for ARVN001 commercialization rights in China.

arcticvision.com
2Product sales (future)
TypeOne Time License
Description

Future revenue from commercialization of pharmaceutical and device products in ophthalmology. Pipeline spans from pre-clinical to commercial stage products covering retinal disease, dry eye, and ocular neuroprotection.

arcticvision.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1ARCATUS
Description

Brand name for ARVN001 (triamcinolone acetonide suprachoroidal injectable suspension) for treatment of uveitic macular edema. Known as XIPERE in the U.S.

arcticvision.com
+2 more records
Core offering1 text field

Arctic Vision is a China-based ophthalmic biotech that develops and commercializes breakthrough therapies for retinal diseases, dry eye, glaucoma, myopia, and presbyopia. Its core offerings include proprietary suprachoroidal space injectable therapy ARVN001 (ARCATUS®/XIPERE®/锋脉®) for uveitic macular edema and the iTEAR® (泪沁) tear neurostimulation device for dry eye, supported by a pipeline spanning preclinical to commercial stage programs combining novel drug delivery, gene therapy, and ophthalmic medical devices.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 38.5% of ARVN001-treated patients achieved ≥15 ETDRS letter vision improvement vs 9.4% in sham group (p<0.001)
+4 more records
Product and service2 records
1ARVN001 (ARCATUS® / XIPERE® / 锋脉®)
CategoryOphthalmic Pharmaceutical
Description

Proprietary suspension of corticosteroid triamcinolone acetonide formulated for suprachoroidal space administration, delivered via the patented SCS Microinjector®. Indicated for uveitic macular edema with demonstrated superior efficacy (38.5% of patients gained ≥15 ETDRS letters vs 9.4% control) and reduced adverse events versus traditional corticosteroid treatments. Marketed in the U.S. by Clearside Biomedical, in Australia as ARCATUS®, in China as 锋脉®, and via Santen Pharmaceutical as commercialization partner in mainland China.

2iTEAR® (泪沁) Tear Neurostimulation Device
CategoryOphthalmic Medical Device
Description

Non-invasive extra-nasal neurostimulation medical device that promotes natural tear production through specific vibration frequency stimulation. A drug-free, preservative-free, and natural treatment for adult patients with dry eye disease caused by insufficient tear secretion or poor tear quality. Awarded the Excellent Product Innovation Award at the Hong Kong Enterprise Innovation Project Selection 2024.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
1MDCO Technology (麦得科科技)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-02
Description

Arctic Vision agreed to acquire MDCO Technology's ophthalmic device business including premium intraocular lens, phakic lens, and refractive device platforms. MDCO becomes a wholly owned subsidiary with operations in Shanghai (biopharmaceutical R&D), Hangzhou (device manufacturing), and California (design and global collaboration). The transaction integrates MDCO's device engineering with Arctic Vision's pharmaceutical capabilities to form a comprehensive ophthalmic innovation ecosystem.

globenewswire.com
2Santen Pharmaceutical
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-11-07
Description

Commercial collaboration agreement where Arctic Vision grants Santen exclusive commercialization rights for ARVN001 in China (excluding Taiwan, Hong Kong, Macau) for treatment of uveitic macular edema and other ophthalmic indications. Arctic Vision to receive up to US$85 million in upfront, milestone payments. Santen brings strong commercial capability with 130+ years of eye health expertise serving 50+ million people in 60+ countries.

arcticvision.com
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2020-03-01
Description

Licensed XIPERE® (ARVN001) for suprachoroidal space injection therapy. Clearside's patented SCS Microinjector® technology enables drug delivery to suprachoroidal space. Arctic Vision obtained exclusive rights for Greater China and South Korea (March 2020), ASEAN and India (August 2021), Australia and New Zealand (September 2021).

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a partner company, providing contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded 1853 with 12,000+ employees in nearly 100 countries.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Japanese clinical stage biotech company developing cell therapy and pharmacological treatments for corneal endothelial dysfunction including Fuchs endothelial corneal dystrophy (FECD) and bullous keratopathy. Founded based on research from Doshisha University, Kyoto.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Medical technology company pioneering patient-focused treatments for ophthalmic diseases using neuromodulation. Based in Issaquah, Washington, backed by BioStar Capital.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Research partnership with Department of Ophthalmology conducting multi-center clinical treatment trials for retinal macular diseases, developing ocular gene therapy for glaucoma, and innovating treatment paradigms for cataract surgery outcomes.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clearside Biomedical (NASDAQ: CLSD) is the originator of the SCS Microinjector suprachoroidal drug delivery platform and developed XIPERE (ARVN001) — the same asset Arctic Vision has licensed for Asia-Pacific, making it the most directly comparable peer in suprachoroidal delivery and ophthalmic drug development.

2Santen Pharmaceutical
TypeBroad incumbent
Description

Santen is a 130+ year Japan-headquartered global ophthalmic specialty pharmaceutical company operating in 60+ countries; it is both Arctic Vision's exclusive China commercialization partner for ARVN001 and a direct competitor in retinal, glaucoma, and dry eye therapeutics across Asia-Pacific.

TypeDirect peer
Description

EyePoint Pharmaceuticals (NASDAQ: EYPT) is a clinical-stage biopharma developing sustained-release ocular drug delivery (DURASERT for retinal diseases including UME), directly comparable to Arctic Vision's suprachoroidal and specialty ophthalmic drug pipeline targeting similar indications.

TypeDirect peer
Description

Ocular Therapeutix (NASDAQ: OCUL) is a clinical-stage biopharma developing sustained-release intracanalicular and intravitreal ophthalmic therapies (e.g., DEXTENZA, OTX-TKI), paralleling Arctic Vision's focus on novel ophthalmic drug delivery for retinal and anterior segment diseases.

TypeDirect peer
Description

Eyenovia (NASDAQ: EYEN) is a clinical-stage ophthalmic biopharma developing microdose array print (MAP) delivery for presbyopia, myopia progression, and mydriasis; an existing Arctic Vision partner and directly comparable in novel ophthalmic drug/device delivery technology.

TypeDirect peer
Description

Olympic Ophthalmics is a US neuromodulation-focused medical technology company pioneering patient-focused treatments for ophthalmic diseases; directly comparable to Arctic Vision's iTEAR extra-nasal neurostimulation device for dry eye disease.

TypeRegional player
Description

Zhaoke Ophthalmology is a China-based ophthalmic pharma company developing innovative therapies for retinal and other eye diseases (listed on HKEX); operates in the same Asia-Pacific ophthalmology specialty pharma category as Arctic Vision but with a China-domestic focus.

TypeRegional player
Description

Eyebright Medical is a leading China-based ophthalmic medical device company specializing in intraocular lenses and ophthalmic surgical products; directly comparable to Arctic Vision's MDCO Technology subsidiary following the 2026 acquisition of premium IOL and refractive device platforms.

TypeBroad incumbent
Description

Alcon is a global ophthalmic medical device and pharmaceutical leader (surgical, vision care, dry eye); Arctic Vision's leadership team includes multiple Alcon alumni and the two compete across retina, glaucoma, dry eye, and surgical device categories in Asia.

TypeBroad incumbent
Description

Bausch + Lomb is a global ophthalmic pharmaceutical, surgical, and vision care company (12,000+ employees, 100+ countries) and an existing Arctic Vision partner; overlaps across ophthalmic pharma, contact lenses, and surgical devices with Arctic Vision's drug-device platform.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Arctic Vision

Ophthalmic Pharmaceuticalsarcticvision.com

Arctic Vision is a Shanghai-based private ophthalmic biopharmaceutical company developing breakthrough therapies for retinal disease, dry eye, and refractive conditions across Asia-Pacific, anchored by its SCS Microinjector platform and lead asset ARVN001 for uveitic macular edema.

What Arctic Vision does

Arctic Vision is a Shanghai-based, privately held ophthalmic biopharmaceutical company founded in 2019 that develops and commercializes innovative therapies for retinal disease, dry eye, and ocular neuroprotection across China and the broader Asia-Pacific region. Its pipeline is anchored by ARVN001 (XIPERE® in the United States, ARCATUS®/锋脉® in Asia-Pacific), a proprietary triamcinolone acetonide suspension formulated for suprachoroidal administration via the patented SCS Microinjector® platform licensed from Clearside Biomedical; ARVN001 is the first and only approved suprachoroidal therapy globally for uveitic macular edema, with approvals from the US FDA, Australian TGA, and Singapore HSA, plus a New Drug Application formally accepted by China's CDE in January 2025. The company's portfolio additionally includes the iTEAR®/沁淯® extra-nasal neurostimulation device for drug-free dry eye treatment (launched in China in May 2024), gene therapy candidates ARVN601 and ARVN901, and multiple preclinical-to-Phase-II assets covering glaucoma, myopia, and presbyopia.

The company operates a dual-engine model that combines in-licensed pharmaceutical development with consumer-oriented device technologies, and in February 2026 announced an agreement to acquire MDCO Technology's ophthalmic device business (premium IOL, phakic lens, and refractive platforms), which will establish wholly-owned subsidiaries in Shanghai for biopharmaceutical R&D, Hangzhou for device manufacturing, and California for design and global collaboration. Commercially, Arctic Vision employs an enterprise field-sales model executed through strategic partnerships and direct regional operations: Santen Pharmaceutical holds exclusive China commercialization rights for ARVN001 (excluding Taiwan, Hong Kong, and Macau), with up to US$85 million in upfront and milestone payments due to Arctic Vision, while the company retains direct commercialization capabilities across Greater China, South Korea, ASEAN countries, India, Australia, and New Zealand.

Arctic Vision generates revenue primarily through licensing and milestone payments rather than direct product sales, with revenue mechanics dominated by upfront fees, development and regulatory milestones, and commercial milestones from partners such as Santen and Clearside Biomedical. The company is backed by Nan Fung Life Sciences, Pivotal bioVenture Partners, Morningside Ventures, Loyal Valley Capital, Tencent Investment, Octagon Capital, and Dr. Adrian Cheng, having raised approximately US$132 million across two disclosed rounds (US$32M Series A in 2020, US$100M Series B in 2021). Leadership is drawn from senior ophthalmic roles at Allergan China, Alcon, Novartis Basel, MSD, and Boehringer Ingelheim, with Founder, Chairman and CEO Dr. Eddy Wu holding 14 patents and 23 academic publications.

Arctic Vision firmographics

Firmographics
Name
Arctic Vision
Legal name
极目峰睿(上海)生物科技有限公司
Website
https://arcticvision.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
Arctic Vision is a Shanghai-based private ophthalmic biopharmaceutical company developing breakthrough therapies for retinal disease, dry eye, and refractive conditions across Asia-Pacific, anchored by its SCS Microinjector platform and lead asset ARVN001 for uveitic macular edema.
Ownership category
akta.pro rank

Arctic Vision industry classification

Industry
Product category
Ophthalmic Pharmaceuticals
NAICS
Ophthalmic Goods Manufacturing (339115), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Surgical & Medical Instruments & Apparatus (3841), Ophthalmic Goods (3851), Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals
SECONDARYHLAKAKAE
Retina & Vitreous Specialists
SECONDARYHLAHAJAH
Cataract Surgery Systems & IOLs (Phaco Systems, IOLs, Intraoperative Aberrometry, Viscoelastics)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHLAKAKAF
Cornea, External Disease & Refractive Surgery (LASIK/PRK)

Keywords

  • Ophthalmic therapeutics
  • Suprachoroidal drug delivery
  • Retinal disease therapy
  • Dry eye treatment
  • Intraocular lens devices

Where Arctic Vision is headquartered

Location

Headquarters

HQ city
Shanghai
HQ country
China
HQ region
Asia

Offices7 records

Markets served

Arctic Vision business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Licensing and milestone payments: Arctic Vision generates revenue through licensing deals including upfront payments, development milestones, regulatory milestones, and commercial milestones. Example: Santen collaboration provides up to US$85 million in upfront and milestone payments for ARVN001 commercialization rights in China.
  2. Product sales (future): Future revenue from commercialization of pharmaceutical and device products in ophthalmology. Pipeline spans from pre-clinical to commercial stage products covering retinal disease, dry eye, and ocular neuroprotection.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Arctic Vision product offering

Product offering

Core offering

Arctic Vision is a China-based ophthalmic biotech that develops and commercializes breakthrough therapies for retinal diseases, dry eye, glaucoma, myopia, and presbyopia. Its core offerings include proprietary suprachoroidal space injectable therapy ARVN001 (ARCATUS®/XIPERE®/锋脉®) for uveitic macular edema and the iTEAR® (泪沁) tear neurostimulation device for dry eye, supported by a pipeline spanning preclinical to commercial stage programs combining novel drug delivery, gene therapy, and ophthalmic medical devices.

Differentiator

Problem solved

Functional benefit

Brands

  • ARCATUS: Brand name for ARVN001 (triamcinolone acetonide suprachoroidal injectable suspension) for treatment of uveitic macular edema. Known as XIPERE in the U.S.
  • 锋脉
  • iTEAR睦沁

Products and services

  • ARVN001 (ARCATUS® / XIPERE® / 锋脉®) Proprietary suspension of corticosteroid triamcinolone acetonide formulated for suprachoroidal space administration, delivered via the patented SCS Microinjector®. Indicated for uveitic macular edema with demonstrated superior efficacy (38.5% of patients gained ≥15 ETDRS letters vs 9.4% control) and reduced adverse events versus traditional corticosteroid treatments. Marketed in the U.S. by Clearside Biomedical, in Australia as ARCATUS®, in China as 锋脉®, and via Santen Pharmaceutical as commercialization partner in mainland China.
  • iTEAR® (泪沁) Tear Neurostimulation Device Non-invasive extra-nasal neurostimulation medical device that promotes natural tear production through specific vibration frequency stimulation. A drug-free, preservative-free, and natural treatment for adult patients with dry eye disease caused by insufficient tear secretion or poor tear quality. Awarded the Excellent Product Innovation Award at the Hong Kong Enterprise Innovation Project Selection 2024.

Quantifiable outcome

  • 38.5% of ARVN001-treated patients achieved ≥15 ETDRS letter vision improvement vs 9.4% in sham group (p<0.001)
  • +4 more outcomes

Companies that use Arctic Vision

Customer profile

Segments4 records

Ideal customer profiles3 records

Arctic Vision technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Arctic Vision partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and minor.

  • MDCO Technology (麦得科科技)coreStrategic or Co-development Partner · 2 February 2026Arctic Vision agreed to acquire MDCO Technology's ophthalmic device business including premium intraocular lens, phakic lens, and refractive device platforms. MDCO becomes a wholly owned subsidiary with operations in Shanghai (biopharmaceutical R&D), Hangzhou (device manufacturing), and California (design and global collaboration). The transaction integrates MDCO's device engineering with Arctic Vision's pharmaceutical capabilities to form a comprehensive ophthalmic innovation ecosystem.
  • Santen PharmaceuticalcoreChannel Partner/ Reseller/ Distributor · 7 November 2024Commercial collaboration agreement where Arctic Vision grants Santen exclusive commercialization rights for ARVN001 in China (excluding Taiwan, Hong Kong, Macau) for treatment of uveitic macular edema and other ophthalmic indications. Arctic Vision to receive up to US$85 million in upfront, milestone payments. Santen brings strong commercial capability with 130+ years of eye health expertise serving 50+ million people in 60+ countries.
  • Clearside BiomedicalcoreTechnology or Integration · 1 March 2020Licensed XIPERE® (ARVN001) for suprachoroidal space injection therapy. Clearside's patented SCS Microinjector® technology enables drug delivery to suprachoroidal space. Arctic Vision obtained exclusive rights for Greater China and South Korea (March 2020), ASEAN and India (August 2021), Australia and New Zealand (September 2021).
  • Bausch + LombminorStrategic or Co-development PartnerListed as a partner company, providing contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded 1853 with 12,000+ employees in nearly 100 countries.
  • ActualEyesminorStrategic or Co-development PartnerJapanese clinical stage biotech company developing cell therapy and pharmacological treatments for corneal endothelial dysfunction including Fuchs endothelial corneal dystrophy (FECD) and bullous keratopathy. Founded based on research from Doshisha University, Kyoto.
  • Olympic OphthalmicsminorStrategic or Co-development PartnerMedical technology company pioneering patient-focused treatments for ophthalmic diseases using neuromodulation. Based in Issaquah, Washington, backed by BioStar Capital.
  • University of Hong Kong - LKS Faculty of MedicineminorStrategic or Co-development PartnerResearch partnership with Department of Ophthalmology conducting multi-center clinical treatment trials for retinal macular diseases, developing ocular gene therapy for glaucoma, and innovating treatment paradigms for cataract surgery outcomes.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Arctic Vision competitors and assessment

Company assessment

Direct peers

  • Clearside Biomedical: Clearside Biomedical (NASDAQ: CLSD) is the originator of the SCS Microinjector suprachoroidal drug delivery platform and developed XIPERE (ARVN001) — the same asset Arctic Vision has licensed for Asia-Pacific, making it the most directly comparable peer in suprachoroidal delivery and ophthalmic drug development.
  • EyePoint Pharmaceuticals: EyePoint Pharmaceuticals (NASDAQ: EYPT) is a clinical-stage biopharma developing sustained-release ocular drug delivery (DURASERT for retinal diseases including UME), directly comparable to Arctic Vision's suprachoroidal and specialty ophthalmic drug pipeline targeting similar indications.
  • Ocular Therapeutix: Ocular Therapeutix (NASDAQ: OCUL) is a clinical-stage biopharma developing sustained-release intracanalicular and intravitreal ophthalmic therapies (e.g., DEXTENZA, OTX-TKI), paralleling Arctic Vision's focus on novel ophthalmic drug delivery for retinal and anterior segment diseases.
  • Eyenovia: Eyenovia (NASDAQ: EYEN) is a clinical-stage ophthalmic biopharma developing microdose array print (MAP) delivery for presbyopia, myopia progression, and mydriasis; an existing Arctic Vision partner and directly comparable in novel ophthalmic drug/device delivery technology.
  • Olympic Ophthalmics: Olympic Ophthalmics is a US neuromodulation-focused medical technology company pioneering patient-focused treatments for ophthalmic diseases; directly comparable to Arctic Vision's iTEAR extra-nasal neurostimulation device for dry eye disease.

Broad incumbents

  • Santen Pharmaceutical: Santen is a 130+ year Japan-headquartered global ophthalmic specialty pharmaceutical company operating in 60+ countries; it is both Arctic Vision's exclusive China commercialization partner for ARVN001 and a direct competitor in retinal, glaucoma, and dry eye therapeutics across Asia-Pacific.
  • Alcon: Alcon is a global ophthalmic medical device and pharmaceutical leader (surgical, vision care, dry eye); Arctic Vision's leadership team includes multiple Alcon alumni and the two compete across retina, glaucoma, dry eye, and surgical device categories in Asia.
  • Bausch + Lomb: Bausch + Lomb is a global ophthalmic pharmaceutical, surgical, and vision care company (12,000+ employees, 100+ countries) and an existing Arctic Vision partner; overlaps across ophthalmic pharma, contact lenses, and surgical devices with Arctic Vision's drug-device platform.

Regional players

  • Zhaoke Ophthalmology (China): Zhaoke Ophthalmology is a China-based ophthalmic pharma company developing innovative therapies for retinal and other eye diseases (listed on HKEX); operates in the same Asia-Pacific ophthalmology specialty pharma category as Arctic Vision but with a China-domestic focus.
  • Eyebright Medical Technology: Eyebright Medical is a leading China-based ophthalmic medical device company specializing in intraocular lenses and ophthalmic surgical products; directly comparable to Arctic Vision's MDCO Technology subsidiary following the 2026 acquisition of premium IOL and refractive device platforms.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Arctic Vision social profiles

Digital presence

Arctic Vision financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Arctic Vision leadership team

Management profile

Number of profiles

Profiles4 records

Arctic Vision subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Arctic Vision funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Arctic Vision M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Arctic Vision

What does Arctic Vision do?

Arctic Vision is a China-based ophthalmic biotech that develops and commercializes breakthrough therapies for retinal diseases, dry eye, glaucoma, myopia, and presbyopia. Its core offerings include proprietary suprachoroidal space injectable therapy ARVN001 (ARCATUS®/XIPERE®/锋脉®) for uveitic macular edema and the iTEAR® (泪沁) tear neurostimulation device for dry eye, supported by a pipeline spanning preclinical to commercial stage programs combining novel drug delivery, gene therapy, and ophthalmic medical devices.

Is Arctic Vision a public or private company?

Arctic Vision is a private company. It is classified as venture growth investor backed and is currently operating.

When was Arctic Vision founded?

Arctic Vision was founded in 2019. It employs 11 to 50 people.

Where is Arctic Vision based?

Arctic Vision is headquartered in Shanghai, China, in the Asia region.

How does Arctic Vision make money?

Two revenue lines are on record. Licensing and milestone payments are the primary driver. The others are product sales (future).

Who are Arctic Vision's main competitors?

Direct peers on record are Clearside Biomedical, EyePoint Pharmaceuticals, Ocular Therapeutix, Eyenovia and Olympic Ophthalmics. Broad incumbents are Santen Pharmaceutical, Alcon and Bausch + Lomb. Regional players are Zhaoke Ophthalmology (China) and Eyebright Medical Technology.

Does Arctic Vision have an API?

No public API is recorded for Arctic Vision.

What industry is Arctic Vision in?

Arctic Vision's product category is Ophthalmic Pharmaceuticals. Its primary akta.pro industry code is HLAIACAK, Ophthalmology Specialty Pharmaceuticals, with a secondary code of HLAKAKAE, Retina & Vitreous Specialists. Its NAICS code is 339115 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Eyes On EyecareArctic Vision acquires MDCO Technology's ophthalmic device businessArctic Vision Limited announced plans to acquire MDCO Technology's ophthalmic device business, which includes premium intraocular lens, implantable contact lens, and refractive device platforms. MDCO will become a wholly-owned subsidiary of Arctic Vision while maintaining operations across Shanghai, Hangzhou, and California, enabling Arctic Vision to establish a "comprehensive ophthalmic innovation ecosystem." The acquisition gives Arctic Vision a direct U.S. footprint through MDCO's California design and global collaboration center.The Manila TimesArctic Vision Announces Deal to Integrate MDCO Technology’s Ophthalmic Device Business to Form a Global Drug-Device Innovation PlatformArctic Vision announced an agreement to acquire MDCO Technology's ophthalmic device business, including intraocular lenses and refractive devices, to enhance its global ophthalmic innovation platform. The transaction will integrate MDCO’s design and manufacturing expertise with Arctic Vision’s pharmaceutical capabilities, expanding its pipeline and R&D.GlobeNewswireArctic Vision Announces Deal to Integrate MDCO Technology’s Ophthalmic Device Business to Form a Global Drug–Device Innovation PlatformArctic Vision, a Shanghai-headquartered global ophthalmic company, has entered into an agreement to acquire MDCO Technology's innovative ophthalmic device business, including its premium intraocular lens, phakic lens, and refractive device platforms. Under the terms of the transaction, MDCO will become a wholly owned subsidiary of Arctic Vision, with combined operations spanning Shanghai for biopharmaceutical R&D, Hangzhou for device manufacturing, and California for design and global collaboration. The integration is intended to create an industry-leading ophthalmic innovation ecosystem combining pharmaceutical and device capabilities, with the companies positioning the platform as structurally prepared for broader global investment and capital market opportunities.Medical Device NetworkArctic Vision to acquire MDCO Technology’s ophthalmic device businessChina-based Arctic Vision has signed an agreement to acquire the ophthalmic device business of MDCO Technology, including intraocular lens, phakic lens, and refractive device platforms. Following the acquisition, MDCO will become a wholly owned subsidiary of Arctic Vision, with combined operations spanning Shanghai, Hangzhou, and California. Arctic Vision CEO Dr. Eddy Wu stated the transaction positions the company for broader global investment participation and future capital market opportunities while expanding its ability to reach more patients in the ophthalmology sector.YahooArctic Vision to acquire MDCO Technology’s ophthalmic device businessChina-based Arctic Vision has signed an agreement to acquire the ophthalmic device business of MDCO Technology, gaining intraocular lens, implantable contact lens, and refractive device platforms. Following the transaction, MDCO will become a wholly owned subsidiary of Arctic Vision, with combined operations spanning Shanghai for biopharmaceutical research, Hangzhou for device R&D and manufacturing, and California for design and global collaboration. The acquisition is positioned as a pivotal step for Arctic Vision's long-term growth strategy, combining MDCO's device engineering expertise developed over nearly two decades with Arctic Vision's existing pharmaceutical R&D capabilities to create what the company describes as a comprehensive ophthalmic innovation ecosystem prepared for broader global investment participation.GlobeNewswireClearside Biomedical’s Asia-Pacific Partner, Arctic Vision, Announced Acceptance of its New Drug Application for ARCATUS® for Regulatory Review in China for the Treatment of Uveitic Macular EdemaArctic Vision's New Drug Application for ARCATUS, a suprachoroidal therapy for uveitic macular edema, was accepted for regulatory review by China's NMPA. The submission is supported by positive topline results from a Phase 3 trial. The product is already approved in the U.S., Australia, and Singapore.GlobeNewswireClearside Biomedical’s Asia-Pacific Partner, Arctic Vision, Announced Acceptance of its New Drug Application for ARCATUS® for Regulatory Review in China for the Treatment of Uveitic Macular EdemaArctic Vision's NDA for ARCATUS, a suprachoroidal therapy for uveitic macular edema, was accepted for regulatory review by China's NMPA. The submission is supported by positive topline results from a Phase 3 trial. The product is already approved in the U.S., Australia, and Singapore.GlobeNewswireClearside Biomedical Announces its Asia-Pacific Partner, Arctic Vision, Received Approval of Suprachoroidal Treatment for Uveitic Macular Edema in Australia and SingaporeClearside Biomedical announced that Arctic Vision's ARCATUS (triamcinolone acetonide) received regulatory approval in Australia and Singapore for treating uveitic macular edema. The drug is part of Clearside's suprachoroidal space injection platform, with Arctic Vision holding exclusive commercialization rights in the region. Arctic Vision also reported positive Phase 3 trial results in July 2024.GlobeNewswireClearside Biomedical Partner Arctic Vision Executes Commercial Collaboration Agreement with Santen Pharmaceutical Co., Ltd for ARVN001 Suprachoroidal Space Injection Therapy for the Treatment of UveitArctic Vision signed a commercial collaboration agreement with Santen Pharmaceutical for ARVN001 (XIPERE) to treat uveitic macular edema in China, excluding Taiwan, Hong Kong, and Macau. The agreement validates Clearside's suprachoroidal delivery platform, with Arctic Vision having a positive Phase 3 trial and regulatory reviews ongoing in Australia and Singapore.